Nexus Clinical Research (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 19 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.16 Cr
- Revenue Growth %
- Profit Growth 37.47%
- Ebitda 88.28%
- Net Worth -14.70%
- Total Assets -12.78%
About Nexus Clinical Research (India)
Nexus Clinical Research (India) Limited (NCRIL) is a Public Limited Indian Non-Government Company incorporated in India on 22 November 2005 and has a history of 19 years and three months. Its registered office is in Thane, Maharashtra, India.
The Corporate was formerly known as Nexus Clinical Research Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹3.16 Cr.
Meghna Bhatt, Amit Bhatt, and Amol Ghate serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U99999MH2005PLC157715
- Company No.
157715
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
22 Nov 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nexus Clinical Research (India)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Meghna Bhatt  | Director | 01-Dec-2005 | Current |
| Amit Bhatt | Director | 15-Dec-2018 | Current |
| Amol Ghate | Additional Director | 04-Jul-2017 | Current |
Financial Performance of Nexus Clinical Research (India).
Nexus Clinical Research (India) Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 37.47% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nexus Clinical Research (India)?
In 2023, Nexus Clinical Research (India) had a promoter holding of 99.79% and a public holding of 0.21%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nexus Central Lab Services Private LimitedMeghna Bhatt and Amit Bhatt are mutual person
Optimal Health India Private LimitedMeghna Bhatt and Amit Bhatt are mutual person
Charges (Loans)
₹31.60 M
₹0
Charges Breakdown by Lending Institutions
- Others : 2.11 Cr
- Dewan Housing Finance Corporation Limited : 1.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Sep 2018 | Others | ₹2.11 Cr | Open |
| 27 May 2015 | Dewan Housing Finance Corporation Limited | ₹1.05 Cr | Open |
How Many Employees Work at Nexus Clinical Research (India)?
Unlock and access historical data on people associated with Nexus Clinical Research (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nexus Clinical Research (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexus Clinical Research (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
